At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Anaplastic Large Cell Lymphoma

Clinical Trial Title: 
A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy and to determine the tolerability of crizotinib given in combination with chemotherapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 22 years of age at the time of study enrollment.
  • Have been newly diagnosed with histologically proven ALCL.
  • Have CD30 positive disease.
  • Have ALK positive disease (defined by local institutional standards).
  • Have stage II, Ill, or IV disease.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office